ReviewAlzheimer's & dementia (New York, N. Y.)
Frontotemporal lobar degeneration therapeutic development pipeline: 2026.
Review in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
introductionFrontotemporal lobar degeneration (FTLD) comprises a group of neuropathological entities underlying a spectrum of clinical syndromes, including behavioral variant frontotemporal dementia, the primary progressive aphasias, progressive supranuclear palsy, and corticobasal syndrome. Their marked biological and clinical heterogeneity is among the reasons why no disease-modifying therapy has been approved.
methodsWe systematically mapped the 2026 therapeutic pipeline by searching ClinicalTrials.gov, the EU Clinical Trials Register, the Clinical Trials Information System, and the International Standard Randomised Controlled Trial Number (ISRCTN) registry for active interventional studies up to May 31, 2026, including Phase 1-3 pharmacological and neuromodulation trials.
resultsThirty-eight active trials were identified (19 pharmacological and 19 neuromodulation), comprising 7 Phase 1 and 11 Phase 2 studies, and 1 Phase 3 study. Neuromodulation accounted for half of the pipeline, predominantly targeting language networks in primary progressive aphasia. Disease-targeted approaches focused mainly on progranulin restoration in DISCUSSION: Although the FTLD pipeline remains largely early stage, advances in mechanistically targeted therapies highlight the importance of proactive case-finding, genetically stratified trial designs, biomarker-guided diagnosis, and mechanism-based therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.